Innovative procedures for micro-elimination of HCV infection in persons who use drugs.

Abstract:

:People who use drugs are a key population in global HCV control. We evaluated the efficacy of an innovative model to eliminate HCV infection in a high-risk population of PWUD in a service for substance use disorder (SUD). Between January 2018 and December 2018, we conducted a prospective, interventional, before and after study, based on audits performed by Infectious Diseases physicians in a SUD facility in Piedimonte Matese, in southern Italy, to improve the knowledge about HCV infection; a shared protocol for screening and linkage to care of patients was implemented. The pre-intervention period was defined as January-December 2017 and the post-intervention period as January-December 2018. The subjects followed up at SUD facility in the pre-intervention and post-intervention periods were 318 and 275, respectively. Compared with the pre-intervention period, the number of anti-HCV-positive subjects tested for HCV RNA was higher in the post-intervention period (91% vs 27%, P < .0001), as was the number who started directly acting antivirals (DAAs). Of the 18 HCV RNA-positive subjects in the pre-intervention period, only 3 (16.6%) started DAA, a percentage decisively lower than that observed after the start of the programme, 63 (84%) of 75 subjects (P < .0001), and all obtained SVR. The data were similar for people who inject drugs (PWID) and non-PWID sub-populations. The use of our innovative model with close interaction between the Infectious Disease Unit and the SUD facility determined a significant increase in HCV RNA testing, linkage to care and the start of DAA in the PWUD population.

journal_name

J Viral Hepat

authors

Messina V,Russo A,Parente E,Russo G,Raimondo T,Salzillo A,Simeone F,Onorato L,Di Caprio G,Pisaturo M,Coppola N

doi

10.1111/jvh.13375

subject

Has Abstract

pub_date

2020-12-01 00:00:00

pages

1437-1443

issue

12

eissn

1352-0504

issn

1365-2893

journal_volume

27

pub_type

杂志文章
  • Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients.

    abstract::Transient elastometry (TE) could provide a more accurate evaluation of the frequency and risk factors of liver fibrosis in hepatitis C virus (HCV) infection than that based on biopsy. The aim of this study was to assess the prevalence of and factors associated with significant liver fibrosis in a large population of H...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2893.2009.01229.x

    authors: Pineda JA,González J,Ortega E,Tural C,Macías J,Griffa L,Burgos A,Grafihco Study Team.

    更新日期:2010-10-01 00:00:00

  • Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection.

    abstract::Hepatitis E virus (HEV) represents one of the foremost causes of acute hepatitis globally. Although there is no proven medication for hepatitis E, pegylated interferon-α (IFN-α) has been used as off-label drug for treating HEV. However, the efficacy and molecular mechanisms of how IFN signalling interacts with HEV rem...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12491

    authors: Zhou X,Xu L,Wang W,Watashi K,Wang Y,Sprengers D,de Ruiter PE,van der Laan LJ,Metselaar HJ,Kamar N,Peppelenbosch MP,Pan Q

    更新日期:2016-04-01 00:00:00

  • Trends of hepatitis A hospitalizations and costs associated with the hospitalization in Spain (2000-2005).

    abstract::The objective of this study was to analyse data related to hospitalization, comorbidities, average stays and costs associated with the hospitalization cases of hepatitis A in Spain, during the period between 2000 and 2005. A retrospective, descriptive study of the epidemiological characteristics of hepatitis A patient...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01075.x

    authors: Arteaga A,Carrasco-Garrido P,de Andres AL,de Miguel AG,Jiménez-García R

    更新日期:2009-04-01 00:00:00

  • Real-world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor-based therapies.

    abstract::The aim of this study was to assess the efficacy and safety of two protocols for retreatment of a cohort of Egyptian patients with chronic hepatitis C (CHC) who relapsed after NS5A inhibitor-based therapy. We conducted a prospective cohort study to assess the safety and efficacy of 12 weeks' retreatment with either co...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13349

    authors: Yousif MM,Ahmed H,Elsadek HM,Shendi AM,Gouda TM,Elsayed IA,Gendia MA,Magdy MM,Lbrahim NF,Sadek AMEM,Zaki AM,Shafeik H,Zahran MH

    更新日期:2020-11-01 00:00:00

  • Assessment of factors associated with pre-diabetes in HCV infection including direct and dynamic measurements of insulin action.

    abstract::Although hepatitis C (HCV) is associated with diabetes, few studies have examined pre-diabetes in this population. We aimed to evaluate factors associated with pre-diabetes in HCV-infected patients, including direct measurement of insulin action. Ninety-seven non-cirrhotic, non-diabetic and HCV-infected patients under...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01568.x

    authors: Mukhtar NA,Ayala C,Maher JJ,Khalili M

    更新日期:2012-07-01 00:00:00

  • Migratory flow and hepatitis delta infection in Italy: A new challenge at the beginning of the third millennium.

    abstract::In Italy, HDV infection endemicity has greatly decreased overtime. Migratory flow may change this scenario as migrants often come from high HDV endemicity areas. Here, we studied characteristics of HDV infection in Italy, particularly addressed to the birth area of subjects. Chronic HBsAg carriers consecutively referr...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13310

    authors: Stroffolini T,Ciancio A,Furlan C,Vinci M,Fontana R,Russello M,Colloredo G,Morisco F,Coppola N,Babudieri S,Ferrigno L,Sagnelli C,Sagnelli E

    更新日期:2020-09-01 00:00:00

  • In vivo immunization in combination with peg-interferon for chronic hepatitis B virus infection.

    abstract::Only in a minority of patients with chronic hepatitis B (CHB) will treatment with interferon (IFN)-alpha or nucleoside analogues lead to sustained virological response. In vivo immunization (IVI) following virus suppression aims to optimize conditions for an effective immune response: following rapid and profound viru...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2893.2007.00841.x

    authors: Sprengers D,van der Molen RG,Binda R,Kusters JG,de Man RA,Niesters HG,Schalm SW,Janssen HL

    更新日期:2007-10-01 00:00:00

  • Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative study.

    abstract::We compared Wisteria floribunda agglutinin-positive Mac-2-binding protein (WFA+ -M2BP) levels between patients with chronic hepatitis B (n=249) and chronic hepatitis C (n=386) based on the degree of liver fibrosis. We examined WFA+ -M2BP levels in patients with F4 (cirrhosis), F3 or more (advanced fibrosis) and F2 or ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12575

    authors: Nishikawa H,Enomoto H,Iwata Y,Kishino K,Shimono Y,Hasegawa K,Nakano C,Takata R,Nishimura T,Yoh K,Ishii A,Aizawa N,Sakai Y,Ikeda N,Takashima T,Iijima H,Nishiguchi S

    更新日期:2016-12-01 00:00:00

  • Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.

    abstract::We compared sustained virological response (SVR) in chronic hepatitis C patients with severe fibrosis treated with pegylated interferon (Peg-IFN) alpha-2b 1.5 microg/kg/week or 0.75 microg/kg/week in combination with ribavirin 800 mg/day for 48 weeks. This was a multicentre randomized controlled study. SVR was observe...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2893.2006.00768.x

    authors: Abergel A,Hezode C,Leroy V,Barange K,Bronowicki JP,Tran A,Alric L,Castera L,Bernard PH,Henquell C,Lafeuille H,Ughetto S,Darcha C,Chevallier M,Martineau N,Dubost S,Randl K,Dhumeaux D,Bommelaer G,Bonny C,French mult

    更新日期:2006-12-01 00:00:00

  • BMI, male sex and IL28B genotype associated with persistently high hepatitis C virus RNA levels among chronically infected drug users up to 23 years following seroconversion.

    abstract::The natural course of serum HCV RNA levels during chronic infection remains unclear. We investigated HCV RNA levels and factors associated with HCV RNA levels for the entire course from HCV seroconversion. We measured HCV RNA levels of 54 HCV seroconverters from the Amsterdam Cohort Studies among drug users at yearly ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12303

    authors: Grady BP,Prins M,Rebers S,Molenkamp R,Geskus RB,Schinkel J

    更新日期:2015-03-01 00:00:00

  • Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients.

    abstract::Hepatitis Be antigen (HBeAg)-negative chronic hepatitis B (CHB) is associated with hepatitis B virus (HBV) variants harbouring changes in the precore region. Most commonly, a G to A point mutation at nucleotide 1896 (m1896) creates a novel translation stop codon that prevents HBeAg production. In the Mediterranean reg...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.1998.00109.x

    authors: Laras A,Koskinas J,Avgidis K,Hadziyannis SJ

    更新日期:1998-07-01 00:00:00

  • A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naïve patients with chronic hepatitis C.

    abstract::A randomized trial was conducted to assess the efficacy of interferon-alpha (IFN) daily in combination with ribavirin in 301 naïve patients with chronic hepatitis C (CHC). Patients were randomized to receive ribavirin 1.2 g daily (QD) for 48 weeks with either IFN 5 MU (thrice weekly) TIW for 8 weeks followed by IFN 3 ...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2893.2003.00439.x

    authors: Tassopoulos NC,Ketikoglou I,Tsantoulas D,Raptopoulou M,Hatzis G,Vafiadis I,Sidiropoulos L,Kanatakis S,Anagnostopoulos G,Sypsa V,Hatzakis A,Hellenic Viral Hepatitis Research Network.

    更新日期:2003-09-01 00:00:00

  • Fas / FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease.

    abstract::The Fas / Fas-ligand (FasL) system is an important death signal pathway in the liver. An enhanced local inflammatory response prompted by FasL expression, which contributes to neutrophil recruitment and interleukin-1 beta (IL-1beta) release, seems to be crucial to chronic liver damage, persistence of viral infections,...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2008.00974.x

    authors: Bortolami M,Kotsafti A,Cardin R,Farinati F

    更新日期:2008-07-01 00:00:00

  • Altered balance between collagen formation and degradation after successful direct-acting antiviral therapy of chronic hepatitis C.

    abstract::The effect of direct-acting antiviral (DAA) therapy on extracellular matrix (ECM) turnover, a prominent feature of chronic hepatitis C (CHC), is unknown. ECM protein degradation and formation generate fragments reflecting the tissue turnover balance when quantified in the blood. PRO-C3 and PRO-C4 reflect type III and ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13416

    authors: Laursen TL,Villesen IF,Leeming DJ,Karsdal MA,Sølund C,Tarp B,Kristensen LH,Holmboe CH,Leutscher P,Laursen AL,Gudmann NS,Grønbaek H

    更新日期:2021-02-01 00:00:00

  • Weight loss during pegylated interferon and ribavirin treatment of chronic hepatitis C*.

    abstract:SUMMARY:Treatment of hepatitis C virus (HCV) infection with interferon (IFN)-alpha, as monotherapy or in combination with ribavirin, is associated with significant side-effects including weight loss. The aim of our study was to describe the evolution of body weight during combination antiviral treatment and to examine ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2005.00637.x

    authors: Seyam MS,Freshwater DA,O'Donnell K,Mutimer DJ

    更新日期:2005-09-01 00:00:00

  • Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy.

    abstract::In chronic hepatitis C, transient elastography (TE) accurately identifies cirrhosis, but its ability to assess significant fibrosis (Metavir > or = F2) is variable. Constitutional and liver disease-related factors may influence TE and here we examined the variables associated with differences. Three hundred consecutiv...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01199.x

    authors: Calvaruso V,Cammà C,Di Marco V,Maimone S,Bronte F,Enea M,Dardanoni V,Manousou P,Pleguezuelo M,Xirouchakis E,Attanasio M,Dusheiko G,Burroughs AK,Craxì A

    更新日期:2010-07-01 00:00:00

  • Modelling the decline and future of hepatitis A transmission in Australia.

    abstract::Hepatitis A incidence has declined in most countries through a combination of prevention measures, augmented through the use of a highly effective vaccine. In Australia, the proportion of the population susceptible to hepatitis A infection has declined over time due to high rates of opportunistic vaccination as well a...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13018

    authors: Jayasundara D,Hui BB,Regan DG,Heywood AE,MacIntyre CR,Wood JG

    更新日期:2019-01-01 00:00:00

  • Reliability and validity of a self-efficacy instrument for hepatitis C antiviral treatment regimens.

    abstract::Self-efficacy or confidence in one's ability to successfully engage in goal-directed behaviour has been shown to influence medication adherence across many chronic illnesses. In the present study, we investigated the psychometric properties of a self-efficacy instrument used during treatment for chronic hepatitis C vi...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01550.x

    authors: Bonner JE,Esserman D,Evon DM

    更新日期:2012-05-01 00:00:00

  • Oxidative burst response of neutrophils primed with PreS1 antigen of hepatitis B virus in patients with chronic hepatitis B and convalescents.

    abstract::The pathogenesis of liver damage in the course of hepatitis B virus (HBV) infection depends on the host's specific and non-specific immune response to various viral antigens. The role of polymorphonuclear neutrophils (PMN) in the natural immune reaction and during secondary microbial infections is well documented. Inc...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.1996.tb00101.x

    authors: Sułowska Z,Pietruszynski R,Dworniak D,Tchórzewski H,Sidorkiewicz M

    更新日期:1996-11-01 00:00:00

  • Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.

    abstract:SUMMARY:Hepatitis C virus (HCV) genotypes 1 and 4 respond less well to pegylated interferon (pegIFN) plus ribavirin (RBV) therapy. For this reason most studies merge these two genotypes when assessing virological response. However, in most trials the HCV genotype 4 population is rather small, and conclusions are mainly...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2893.2008.01015.x

    authors: Martín-Carbonero L,Puoti M,García-Samaniego J,De Luca A,Losada E,Quinzan G,Bruno R,Mariño A,González M,Núñez M,Soriano V

    更新日期:2008-10-01 00:00:00

  • Inpatient resource utilization, disease severity, mortality and insurance coverage for patients hospitalized for hepatitis C virus in the United States.

    abstract::Although the incidence of new hepatitis C virus (HCV) infection has fallen, HCV-related complications are on the rise. Our aim was to assess and describe the 2005-2009 national inpatient mortality and resource utilization trends for patients with HCV. Data from the National Inpatient Sample (NIS) and the National Hosp...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12262

    authors: Younossi ZM,Otgonsuren M,Henry L,Arsalla Z,Stepnaova M,Mishra A,Venkatesan C,Hunt S

    更新日期:2015-02-01 00:00:00

  • Public health clinic-based hepatitis C testing and linkage to care in Baltimore.

    abstract::Testing and linkage to care are important determinants of hepatitis C virus (HCV) treatment effectiveness. Public health clinics serve populations at high risk of HCV. We investigated their potential to serve as sites for HCV testing, initiation of and linkage to HCV care. Cross-sectional study of patients accessing s...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12507

    authors: Falade-Nwulia O,Mehta SH,Lasola J,Latkin C,Niculescu A,O'Connor C,Chaulk P,Ghanem K,Page KR,Sulkowski MS,Thomas DL

    更新日期:2016-05-01 00:00:00

  • Morbidity and mortality of recurrent hepatitis C infection after orthotopic liver transplantation.

    abstract::Through molecular virological testing it is now clear that HCV reinfection of the allograft is virtually universal in liver transplant recipients. Although histopathological recurrence of hepatitis C occurs in the majority of patients, it is absent in a substantial minority. To date, no prognostic factors, other than ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2893.1997.tb00172.x

    authors: Vierling JM,Villamil FG,Rojter SE,Camacho KB,Goldman DE

    更新日期:1997-01-01 00:00:00

  • Prevalence of HBsAg/HBeAg amongst 1 936 801 couples preparing for pregnancy in rural China: An observational study.

    abstract::There are few extant studies on the prevalence of HBV infection in couples preparing for pregnancy. We assessed the prevalence of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) in couples preparing for pregnancy in rural China, and the association between HBV prevalence and the statuses of HBsAg...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12693

    authors: Liu J,Zhang S,Wang Q,Shen H,Zhang M,Zhang Y,Yan D,Liu M

    更新日期:2017-08-01 00:00:00

  • Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir.

    abstract::It is unknown whether dynamic changes of liver stiffness measurement (LSM) can predict the reversibility of fibrosis. Therefore, we evaluated the utility of LSM changes in predicting histological changes of fibrosis in patients with chronic hepatitis B (CHB) on antiviral therapy. In a prospective cohort of CHB patient...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13058

    authors: Kong Y,Sun Y,Zhou J,Wu X,Chen Y,Piao H,Lu L,Ding H,Nan Y,Jiang W,Xu Y,Xie W,Li H,Feng B,Shi G,Chen G,Li H,Zheng H,Cheng J,Wang T,Liu H,Lv F,Shao C,Mao Y,Sun J,Chen T,Han T,Han Y,Wang L,Ou X,Zha

    更新日期:2019-05-01 00:00:00

  • Anti-interferon-α neutralizing antibody is associated with nonresponse to pegylated interferon-α plus ribavirin in chronic hepatitis C.

    abstract::Pegylated interferon-α (PEG-IFN-α) plus ribavirin (RBV) treatment fails to achieve a sustained virological response (SVR) in approximately 20-50% of patients with chronic hepatitis C virus (HCV) infection. We assessed the contribution of an anti-IFN-α neutralizing antibody (NAb) on the nonresponse to treatment. NAbs w...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2012.01598.x

    authors: Matsuda F,Torii Y,Enomoto H,Kuga C,Aizawa N,Iwata Y,Saito M,Imanishi H,Shimomura S,Nakamura H,Tanaka H,Iijima H,Tsutsui H,Tanaka Y,Nishiguchi S

    更新日期:2012-10-01 00:00:00

  • Hepatitis C: an epidemiological review.

    abstract::The aim of the study was to analyse the current literature regarding the mode of transmission of HCV and its global prevalence in different groups of people. A systematic review of the literature on the epidemiology of hepatitis C from 1991 to 2000 using computerized bibliographic databases which include Medline, Curr...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2893.2002.00329.x

    authors: Memon MI,Memon MA

    更新日期:2002-03-01 00:00:00

  • Role of nitric oxide synthase genes in hepatitis E virus infection.

    abstract::Hepatitis E virus (HEV) is the most common cause of endemic and epidemic acute hepatitis. A correlation between iNOS, eNOS polymorphisms, levels and severity of disease has been reported, and here, we examined the role of iNOS and eNOS gene polymorphisms and their levels in HEV-related acute viral hepatitis and acute ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12186

    authors: Hazam RK,Deka M,Kar P

    更新日期:2014-01-01 00:00:00

  • Comparison of deaths related to Hepatitis C and AIDS in Scotland.

    abstract::In resource-rich countries, the incidence of and mortality from AIDS has fallen dramatically since the introduction of combination antiretroviral therapy. In contrast, developed countries have observed increases in the public health burden associated with the hepatitis C virus (HCV). We compared past and current trend...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2007.00876.x

    authors: Palmateer NE,Hutchinson SJ,McLeod A,Codere G,Goldberg DJ

    更新日期:2007-12-01 00:00:00

  • Human leucocyte interferon-alpha in chronic hepatitis C resistant to recombinant or lymphoblastoid interferon-alpha: a randomized controlled trial.

    abstract::Patients with biopsy-proven chronic hepatitis C, who failed to respond to a previous course of either recombinant (rIFN-alpha) or lymphoblastoid (Ly IFN-alpha) interferon-alpha, were randomized to receive either leucocyte (Le) IFN-alpha (patients) or a second course of the same IFN-alpha (controls), to compare the eff...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2893.1997.00146.x

    authors: Gaeta GB,Di Virgilio D,Russo G,Stornaiuolo G,Nicolella U,Colella F,Grimaldi M,Pasquale G,Giusti G

    更新日期:1997-05-01 00:00:00